10.00 - 12.00
SESSION: CLINICAL STUDIES
Chairpersons: Prof. Wojciech Jurczak, Marek Dudziński PhD
Chairpersons: Prof. Wojciech Jurczak, Marek Dudziński PhD
10.00 - 10.15
The Role of Medical Research Agency in the development of clinical studies in Poland | Dominika Substelny
10.15 - 10.30
GUEST LECTURE 
Pratia – where clinical trials work | Małgorzata Gerjatowicz
Pratia – where clinical trials work | Małgorzata Gerjatowicz
10.30 - 10.45
GUEST LECTURE .png)
The hospital knows more than it can find. An innovative AI-powered system for automatic
identification of patients for clinical trials in hospital databases | Marek Dudziński, PhD
The hospital knows more than it can find. An innovative AI-powered system for automatic
identification of patients for clinical trials in hospital databases | Marek Dudziński, PhD
10.45 - 11.00
GUEST LECTURE 
Poland as a partner in global clinical development in hemato-oncology – romaciclib case study (RVU120) | Kamil Sitarz, PhD
Poland as a partner in global clinical development in hemato-oncology – romaciclib case study (RVU120) | Kamil Sitarz, PhD
11.00 - 11.15
GUEST LECTURE 
Bexobrutideg (NX-5948), a novel BTK degrader, in R/R CLL: ongoing and planned clinical trials | Matt Yates, PhD
Bexobrutideg (NX-5948), a novel BTK degrader, in R/R CLL: ongoing and planned clinical trials | Matt Yates, PhD
(lecture in English, translation is available)
11.15 - 12.00
Panel discussion
Dominika Substelny; Małgorzata Gerjatowicz; Marek Dudziński, PhD; Kamil Sitarz, PhD; Matt Yates, PhD; Prof. Wojciech Jurczak
Dominika Substelny; Małgorzata Gerjatowicz; Marek Dudziński, PhD; Kamil Sitarz, PhD; Matt Yates, PhD; Prof. Wojciech Jurczak
12.00 - 13.00
Lunch
13.00 - 13.05
BEGINNING OF THE CONFERENCE
Prof. Monika Długosz-Danecka, Prof. Wojciech Jurczak, Prof. Lidia Gil, Prof. Iwona Hus, Prof. Janusz Ryś
Prof. Monika Długosz-Danecka, Prof. Wojciech Jurczak, Prof. Lidia Gil, Prof. Iwona Hus, Prof. Janusz Ryś
13.05 - 14.40
SESSION 1 | HODGKIN LYMPHOMA AND T-CELL LYMPHOMAS
Chairpersons: Prof. Wojciech Jurczak, Prof. Jan Walewski, Prof. Janusz Ryś
Chairpersons: Prof. Wojciech Jurczak, Prof. Jan Walewski, Prof. Janusz Ryś
13.05 - 13.30
How much chemotherapy do we need in Hodgkin lymphoma? | Prof. Stephen Ansell
(lecture in English, translation is available)
13.30 - 13.45
Sponsored lecture 
From the HD21 study to everyday clinical practice: the role of brentuximab vedotin in the treatment of Hodgkin lymphoma according to the BrECADD regimen | Prof. Justyna Rybka
From the HD21 study to everyday clinical practice: the role of brentuximab vedotin in the treatment of Hodgkin lymphoma according to the BrECADD regimen | Prof. Justyna Rybka
13.45 - 14.00
Immunotherapy in Hodgkin lymphoma | Prof. Marcin Pasiarski
14.00 - 14.15
The role of allogeneic transplants in Hodgkin lymphoma and T-cell lymphomas | Prof. Jan Walewski
14.15 - 14.20
Case presentation – introduction to the debate | Anna Drosik-Kwaśniewska, PhD
14.20 - 14.40
Debate: Optimal treatment sequence in Hodgkin lymphoma and T-cell lymphomas | Prof. Stephen Ansell; Prof. Justyna Rybka; Prof. Marcin Pasiarski; Prof. Jan Walewski; Anna Drosik-Kwaśniewska, PhD; Prof. Wojciech Jurczak; Prof. Janusz Ryś
14.40 - 14.55
Coffee break
14.55 - 17.00
SESSION 2 | INDOLENT B-CELL LYMPHOMAS
Chairpersons: Prof. Monika Długosz-Danecka, Prof. Ewa Lech-Marańda
Chairpersons: Prof. Monika Długosz-Danecka, Prof. Ewa Lech-Marańda
14.55 - 15.20
“Chemo or no chemo” as a future SOC in indolent lymphoma | Prof. Pavel Klener
(lecture in English, translation available)
15.20 - 15.35
Individualisation of MCL treatment | Joanna Romejko-Jarosińska, PhD, professor of NIO-PIB
15.35 - 15.50
Zanubrutinib – current treatment options for indolent lymphomas | Ewa Paszkiewicz-Kozik, PhD, professor of NIO-PIB
15.50 - 16.05
Sponsored lecture 
CD19 meets CD20 – a new chapter in the second-line treatment for follicular lymphoma with tafasitamab | Katarzyna Brzeźniakiewicz-Janus, PhD, professor of UZ
CD19 meets CD20 – a new chapter in the second-line treatment for follicular lymphoma with tafasitamab | Katarzyna Brzeźniakiewicz-Janus, PhD, professor of UZ
16.05 - 16.20
Follicular lymphoma – management in high-risk cases | Joanna Drozd-Sokołowska, PhD
16.20 - 16.35
MZL/WM – the role of immunochemotherapy, BTK inhibitors and degraders | Prof. Ewa Lech-Marańda
16.35 - 16.40
Case presentation – introduction to the debate | Agnieszka Kopacz, PhD
16.40 - 17.00
Debate: Does the choice of first-line treatment in indolent lymphomas matter? | Prof. Pavel Klener; Joanna Romejko-Jarosińska, PhD, professor of NIO-PIB; Ewa Paszkiewicz-Kozik, PhD, professor of NIO-PIB; Joanna Drozd-Sokołowska, PhD; Prof. Ewa Lech-Marańda; Agnieszka Kopacz, PhD; Prof. Monika Długosz-Danecka
17.00 - 17.15
Coffee break
17.15 - 18.35
SESSION 3 | AGGRESSIVE LYMPHOMAS
Chairpersons: Prof. Grzegorz Nowakowski, Prof. Tomasz Wróbel
Chairpersons: Prof. Grzegorz Nowakowski, Prof. Tomasz Wróbel
17.15 - 17.40
Immunomodulation in LBCL: lenalidomide and beyond | Prof. Grzegorz Nowakowski
(lecture in English, translation available)
17.40 - 17.55
Current standards of treatment for aggressive lymphomas | Prof. Wojciech Jurczak
17.55 - 18.10
Sponsored lecture 
Targeted chemotherapy – new possibilities | Prof. Tomasz Wróbel
Targeted chemotherapy – new possibilities | Prof. Tomasz Wróbel
18.10 - 18.15
Case presentation – introduction to the debate | Kamil Wdowiak, PhD
18.15 - 18.35
Debate: Do we have an alternative to T cell engagers in the treatment of relapsed/refractory aggressive lymphomas? | Prof. Grzegorz Nowakowski; Prof. Wojciech Jurczak; Prof. Tomasz Wróbel; Kamil Wdowiak, PhD
20.00
Dinner
09.00 - 11.05
SESSION 4 | CHRONIC LYMPHATIC LEUKEMIA
Chairpersons: Prof. Monika Długosz-Danecka, Prof. Iwona Hus
Chairpersons: Prof. Monika Długosz-Danecka, Prof. Iwona Hus
09.00 - 09.25
The optimal time-limited regimens in CLL | Prof. Barbara Eichhorst
(lecture in English, translation is available)
09.25 - 09.40
Sponsored lecture 
Venetoklax – a unique mechanism of action and high efficacy | Elżbieta Kalicińska, PhD
Venetoklax – a unique mechanism of action and high efficacy | Elżbieta Kalicińska, PhD
09.40 - 09.55
Sponsored lecture 
I+V regimen: key evidence, real benefits, everyday practice | Paweł Steckiewicz, PhD
I+V regimen: key evidence, real benefits, everyday practice | Paweł Steckiewicz, PhD
09.55 - 10.10
Sponsored lecture 
Acalabrutinib in CLL: clinical evidence that shapes standards | Bartosz Puła, PhD
Acalabrutinib in CLL: clinical evidence that shapes standards | Bartosz Puła, PhD
10.10 - 10.25
Zanubritinib and Sonrotoclax – together or separately | Marta Morawska, PhD
10.25 - 10.40
Sponsored lecture 
Modern treatment of patients with relapsed/refractory CLL | Prof. Iwona Hus
Modern treatment of patients with relapsed/refractory CLL | Prof. Iwona Hus
10.40 - 10.45
Case presentation – introduction to the debate | Iwona Grygoruk-Wiśniowska, PhD
10.45 - 11.05
Debate: Can we achieve a functional cure in patients with CLL? | Prof. Barbara Eichhorst; Elżbieta Kalicińska, PhD; Paweł Steckiewicz, PhD; Bartosz Puła, PhD; Marta Morawska, PhD; Prof. Iwona Hus; Iwona Grygoruk-Wiśniowska, PhD; Prof. Monika Długosz-Danecka; Prof. Wojciech Jurczak
11.05 - 11.20
Coffee break
11.20 - 13.10
SESSION 5 | T-CELL-ENGAGING THERAPIES
Chairpersons: Prof. Sebastian Giebel, Prof. Wojciech Jurczak
Chairpersons: Prof. Sebastian Giebel, Prof. Wojciech Jurczak
11.20 - 11.45
CAR-T when late is too late | Prof. Gloria Iacoboni
(lecture in English, translation is available)
11.45 - 12.00
CAR-T – one idea, different cell therapies | Prof. Lidia Gil
12.00 - 12.15
Bridge or not to bridge | Prof. Sebastian Giebel
12.15 - 12.30
Bispecific antibodies – new indications, the most promising combinations | Prof. Sebastian Grosicki
12.30 - 12.45
Sponsored lecture
Time-limited bispecific antibody therapies | Prof. Monika Długosz-Danecka
Time-limited bispecific antibody therapies | Prof. Monika Długosz-Danecka
12.45 - 12.50
Case presentation – introduction to the debate | Ewa Pietrusza, PhD
12.50 - 13.10
Debate: CAR-T vs. bispecific antibodies, victory or draw? | Prof. Gloria Iacoboni; Prof. Lidia Gil; Prof. Sebastian Giebel; Prof. Sebastian Grosicki; Prof. Monika Długosz-Danecka; Ewa Pietrusza, PhD; Prof. Wojciech Jurczak
13.10 - 13.25
Coffee break
13.25 - 15.15
SESSION 6 | MULTIPLE MYELOMA
Chairpersons: Prof. Dominik Dytfeld, Prof. Krzysztof Giannopoulos
Chairpersons: Prof. Dominik Dytfeld, Prof. Krzysztof Giannopoulos
13.25 - 13.50
Beyond Deep Response: Is Functional Cure the Real Goal in Multiple Myeloma? | Prof. Roman Hájek
(lecture in English, translation is available)
13.50 - 14.05
Sponsored lecture
Long-term survival depends on the choice of first-line treatment regimen in multiple myeloma | Prof. Krzysztof Giannopoulos
Long-term survival depends on the choice of first-line treatment regimen in multiple myeloma | Prof. Krzysztof Giannopoulos
14.05 - 14.20
Sponsored lecture
CAR-T – pushing the boundaries in the treatment of multiple myeloma | Prof. Artur Jurczyszyn
CAR-T – pushing the boundaries in the treatment of multiple myeloma | Prof. Artur Jurczyszyn
14.20 - 14.35
Evolution of targeted chemotherapy in the era of bispecific antibodies | Prof. Krzysztof Jamroziak
14.35 - 14.50
High-risk patients: the superiority of targeted treatment over intensive chemotherapy | Prof. Dominik Dytfeld
14.50 - 14.55
Case presentation – introduction to the debate | Marek Rodzaj, PhD
14.55 - 15.15
Debate: Multiple myeloma – a treatment strategy, not a sequential use of different reimbursed regimens | Prof. Roman Hájek; Prof. Krzysztof Giannopoulos; Prof. Artur Jurczyszyn; Prof. Krzysztof Jamroziak; Prof. Dominik Dytfeld; Marek Rodzaj, PhD
15.15 - 15.25
CONFERENCE CLOSING REMARKS
Prof. Monika Długosz-Danecka, Prof. Wojciech Jurczak, Prof. Lidia Gil, Prof. Iwona Hus
Prof. Monika Długosz-Danecka, Prof. Wojciech Jurczak, Prof. Lidia Gil, Prof. Iwona Hus
15.25 - 16.25
Lunch